Wegovy vs Rybelsus (Being Discontinued in the US): One Molecule, One Label Apart

Wegovy (semaglutide, Novo Nordisk) vs Rybelsus (oral semaglutide, Novo Nordisk)

Last verified October 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

Both are semaglutide from Novo Nordisk. Only Wegovy is approved for weight management: the weekly injection since June 2021, and now also a daily tablet that goes up to 25 mg. Rybelsus is a daily tablet approved for type 2 diabetes in September 2019, with the fasting window oral absorption requires, and in the US it is being discontinued in favor of Ozempic tablets. Pricing follows the label: the Wegovy pen is $349 a month self-pay and the Wegovy tablet $149–$299 by dose, while Ozempic tablets, the Rybelsus replacement, also run $149–$299. It is the same drug, and the label decides both what you can get and what you pay.

Side-by-side comparison

Wegovy vs Rybelsus, side by side
FieldWegovyRybelsus
FDA-approved for weight lossYes (June 2021)No (T2D only, Sept 2019)
Mean weight loss in the pivotal trial-14.9% at 68 weeks (STEP-1, 2.4 mg)-3.7 kg (about 4%) at 26 weeks at 14 mg, in type 2 diabetes (PIONEER 1)
Route of administrationWeekly subcutaneous injectionDaily oral tablet
Dosing protocolInject once weekly, any time of dayFasting, 4 oz water, wait 30 min before food/drink/other meds
Maximum approved dose2.4 mg weekly14 mg daily. The 25 mg oral semaglutide is the Wegovy tablet, approved for weight; Ozempic tablets stop at 9 mg
Cardiovascular benefitMACE -20% in SELECT trial (overweight/obesity, no diabetes)MACE -14% (HR 0.86) in the SOUL trial (type 2 diabetes at high cardiovascular risk, 14 mg)
Cash price (NovoCare, monthly)$349 self-pay (pen); tablet $149–$299 by doseOzempic tablets, its US replacement: $149–$299 by dose
Nausea rate~44% (STEP-1)20% at 14 mg (label, placebo-controlled trials)
Boxed warningThyroid C-cell tumorsThyroid C-cell tumors
Insurance coverage for weight lossIncreasingly covered with PARarely covered for weight loss (off-label)

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Wegovy — semaglutide

from $47 /mo

463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.

Where to get semaglutide — a selection of sellers, not a price ranking

Rybelsus — oral semaglutide

from $47 /mo

463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.

Where to get semaglutide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Wegovy or Rybelsus?

Wegovy recorded Yes (June 2021); Rybelsus recorded No (T2D only, Sept 2019). These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.

Are Wegovy and Rybelsus the same drug?

Chemically, yes — both are semaglutide. They are sold under different names for different approved uses, and usually at different doses and different prices. That is a labeling and commercial distinction, not a pharmacological one, which is why a prescription for one is not automatically interchangeable with the other at the pharmacy counter.

Is Wegovy or Rybelsus cheaper?

On the manufacturers' own cash pricing: Wegovy at $349 self-pay (pen); tablet $149–$299 by dose, Rybelsus at Ozempic tablets, its US replacement: $149–$299 by dose. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

Does either one have better cardiovascular evidence?

Neither has a clear edge. Wegovy: MACE -20% in SELECT trial (overweight/obesity, no diabetes). Rybelsus: MACE -14% (HR 0.86) in the SOUL trial (type 2 diabetes at high cardiovascular risk, 14 mg). This matters more than it first appears — a drug with a completed outcomes trial has evidence about events that matter, not only about weight, and that is often what decides coverage.

How is each one taken?

Wegovy: Weekly subcutaneous injection. Rybelsus: Daily oral tablet. Worth weighing honestly against your own habits — the best drug for you is partly the one you will still be taking in eight months, and a dosing routine that does not fit a life gets abandoned.

What does a compounded version of each actually cost?

Compounders sell the molecule, not either brand, so one figure covers both: across the 734 sellers in this register, the cheapest standing monthly cash price we hold for compounded semaglutide is $47 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Wegovy to Rybelsus?

People move between them regularly, since it is the same molecule — but the dose ladders differ, so a prescriber has to map where you land rather than matching the number. Do not assume your current dose transfers.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Wilding JPH, Batterham RL, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1) N Engl J Med. 2021. PMID: 33567185.
  2. 2.Lincoff AM, Brown-Frandsen K, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) N Engl J Med. 2023. PMID: 37952131.
  3. 3.Knop FK, Aroda VR, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet. 2023. PMID: 37385278.
  4. 4.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets — Prescribing Information (revised January 2026). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  5. 5.McGuire DK, Marx N, Mulvagh SL, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL). N Engl J Med. 2025. PMID: 40162642.
  6. 6.Novo Nordisk. Ozempic (semaglutide) pill available in the US starting May 4 (press release, May 1, 2026). Novo Nordisk US newsroom. 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
  7. 7.Novo Nordisk. WEGOVY (semaglutide) injection and tablets — Prescribing Information. DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b

See the full drug-vs-drug verdict index or provider rankings.